Cytokinetics Inc (CYTK) is a Healthcare · Biotechnology company listed on NASDAQ. Price $68.78 (-1.63%), Market cap $7.87B, 52-week low–high $29.84 ~ $70.10.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and
Financial statements, price targets, institutional (13F) holdings and related news for Cytokinetics Inc are updated in real time on BlackAll Trade.
Cytokinetics Inc trades at $68.78 (-1.63%). Real-time quotes and charts are available on BlackAll Trade.
Cytokinetics Inc has a market cap of about $7.87B.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating